Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 13/20 | 0.61 |
| ▸ | CLK2 | P49760 | 6/20 | 0.55 |
| ▸ | CLK1 | P49759 | 3/20 | 0.55 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | CLK3 | P49761 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485816 | 0.90 | MAP3K5 (0.73) | MAP3K5CLK2CLK1HRH1PDGFRB | |
| SCHEMBL3485638 | 0.87 | MAP3K5 (0.69) | MAP3K5CLK2CLK1HRH1PDGFRB | |
| SCHEMBL3485377 | 0.85 | MAP3K5 (0.58) | MAP3K5CLK2CLK1HRH1PDGFRB | |
| SCHEMBL3487503 | 0.82 | MAP3K5 (0.77) | MAP3K5CLK2CLK1HRH1PDGFRB | |
| SCHEMBL3486459 | 0.82 | MAP3K5 (0.59) | MAP3K5CLK2CLK1HRH1PDGFRB | |
| Hydrochloric Acid SCHEMBL3486671 | 0.82 | MAP3K5 (0.58) | MAP3K5CLK2CLK1HRH1PDGFRB | |
| SCHEMBL3487230 | 0.82 | MAP3K5 (0.82) | MAP3K5CLK2CLK1HRH1PDGFRB | |
| SCHEMBL3487163 | 0.80 | CLK2 (0.67) | MAP3K5CLK2CLK1RETCDK2 | |
| SCHEMBL3486443 | 0.80 | MAP3K5 (0.79) | MAP3K5CLK2CLK1RETCDK2 | |
| Hydrochloric Acid SCHEMBL3486202 | 0.79 | MAP3K5 (0.77) | MAP3K5CLK2CLK1RETCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8715678-B2 | Method for inhibiting the formation of SET1 family core complexes | SYRACUSE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130203167-A1 | METHOD FOR INHIBITING THE FORMATION OF SET1 FAMILY CORE COMPLEXES | SYRACUSE UNIVERSITY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100022002-A1 | METHOD FOR INHIBITING THE FORMATION OF SET1 FAMILY CORE COMPLEXES | SYRACUSE UNIVERSITY | 2010-01-28 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | MAP3K5 42/4885CLK2 2521/4885CLK1 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.